- Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
- Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
- Rigel Reports First Quarter 2025 Financial Results and Provides . . .
Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R R) lower-risk MDS
- Press Releases :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R R mIDH1 AML in the Journal of Hematology Oncology Nov 12, 2025 8:05am EST
- Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases
- Who We Are :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
- Management Team :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
- Rigel Provides Business Update and 2025 Outlook
Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R R) lower-risk myelodysplastic syndrome (MDS)
|